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Abstract
Studies of influenza virus evolution under controlled experimental conditions can provide a better understanding of the
consequences of evolutionary processes with and without immunological pressure. Characterization of evolved strains
assists in the development of predictive algorithms for both the selection of subtypes represented in the seasonal influenza
vaccine and the design of novel immune refocused vaccines. To obtain data on the evolution of influenza in a controlled
setting, naı ¨ve and immunized Guinea pigs were infected with influenza A/Wyoming/2003 (H3N2). Virus progeny from nasal
wash samples were assessed for variation in the dominant and other epitopes by sequencing the hemagglutinin (HA) gene
to quantify evolutionary changes. Viral RNA from the nasal washes from infection of naı ¨ve and immune animals contained
6% and 24.5% HA variant sequences, respectively. Analysis of mutations relative to antigenic epitopes indicated that
adaptive immunity played a key role in virus evolution. HA mutations in immunized animals were associated with loss of
glycosylation and changes in charge and hydrophobicity in and near residues within known epitopes. Four regions of HA-1
(75–85, 125–135, 165–170, 225–230) contained residues of highest variability. These sites are adjacent to or within known
epitopes and appear to play an important role in antigenic variation. Recognition of the role of these sites during evolution
will lead to a better understanding of the nature of evolution which help in the prediction of future strains for selection of
seasonal vaccines and the design of novel vaccines intended to stimulated broadened cross-reactive protection to
conserved sites outside of dominant epitopes.
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Introduction
Globally, influenza is responsible for 250,000 to 500,000 deaths
annually and is considered one of the most important respiratory
pathogens of humans [1,2,3]. In the majority of the past ten years,
H3N2 has dominated in prevalence of infection and disease over
H1N1, H2N2, and influenza B. In the United States alone,
approximately 5–20% of the population contracts influenza
illnesses leading to about 240,000 hospitalizations and 40,000
deaths with the majority due to H3N2 [4,5]. In addition to
morbidity and mortality, influenza causes an annual economic
impact in the range of $80B in this country alone [5]. Although
vaccination is one of the most important preventative methods, the
current vaccine design is far from perfect. Due to the antigenic
evolution of the virus and strain-specific immune responses of the
host, the vaccine requires reformulation every year or two to offer
significant protection against circulating strains not represented in
the vaccine. In the 2007–08 seasons, for example, the vaccine was
composed of viruses antigenically similar to A/Solomon Islands
(H1), A/Wisconsin (H3) and B/Malaysia (Victoria). According to
the results of antigenic surveillance done by CDC, 91% of the
H1N1 viruses circulating in 2007–8 were similar to the vaccine
strain, but only 29% of the H3N2 strains were characterized as A/
Wisconsin-like virus. The vaccine was not a good match against
circulating strains in 2007–8, causing larger than normal numbers
morbidity and mortality predominantly due to Brisbane/2007 -
like viruses. In an effort to match the newly emerged dominant
virus strain, the Brisbane/2007 was then chosen to be the H3N2
component for the 2008–9 and 2009–2010 Northern Hemisphere
vaccines. Due to the uncertainty in the composition of future
evolved strains, there are no guarantees that the subtype selected
for a vaccine will be a close enough match against future strains
that emerge from antigenic drift. Thus, improvements in
predictive capabilities could lead to more effective vaccines.
The majority of the efforts expended to predict seasonal
circulating influenza strains and the subsequent selection of the
most appropriate vaccine strains are performed on an uncon-
trolled background of accumulated influenza immunity and viral
evolution in the human host. The use of human natural infection
data, rather than viral evolution data derived from well-controlled
animal studies confounds the interpretation of both the serological
and sequence data. The presence of various serologically cross-
reactivate strains and subtypes of the virus along with residual host
cross-reactivity due to prior infection and vaccination from
previous years also adds layers of complexity to the interpretation
of serological and virological data [6]. This loss of specificity of the
recall immune response to some strains imparts immune selection
in ways that are not fully understood when it comes to the
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appear useful to derive more in-depth understandings of influenza
evolution in more controlled experimental and immune settings,
so as to augment the predictive power of those tasked with
choosing the composition of seasonal vaccine strains. Furthermore,
novel technologies, such as immune refocusing, which utilizes
information about the immunodominance of the antigenic sites for
their removal and have succeeded in preclinical studies of inducing
enhanced cross-reactive immunity would benefit from such data
[7]. Thus, we studied the evolution of the hemagglutinin (HA)
protein of a selected H3N2 seasonal strain of virus in the Guinea
pig animal model [8].
Influenza viruses have negative-strand segmented genomes that
are replicated by a viral polymerase that has a high error rate
[9,10,11]. The viral polymerase subunits PB1, PB2, PA, and NP
form complexes that replicate the viral RNA strands with error
rates in the range of 10
24 to 10
25 misincorporations per
nucleotide per round of RNA synthesis [10,11]. Although the
majority of variants produced by the high mutation rate are
expected to possess reduced viability, the availability of a pool of
variants facilitates rapid evolution. Changes in amino acids located
in immunodominant epitopes foster escape from immune
pressure. Misincorporations by the replicase have been thought
to occur randomly throughout the genome and supply the pool of
variants from which evolutionarily fit strains develop. Therefore,
highly variant domains are likely signs of immunological selection.
Several animal models have been used to study influenza
infection and immunity. Although mouse, rat, and ferret models
dominate the recent literature [8,12,13,14,15], publications from
Lowen et al and Bushnell et al have advanced the Guinea pig as a
relevant model of human influenza virus infection, transmission,
and serology [8,16]. Guinea pigs are susceptible to infection by
unadapted human influenza virus strains and can transmit the
virus to cage mates via aerosol [8]. The infection is largely
centered in the upper respiratory tract and produces little outward
signs of disease. In the present study, virus progeny recovered from
nasal washes were examined for HA sequence variations. The data
show a non-random propensity for mutations in the major
antigenic sites. The present study examines the variations in the
HA of A/Wyoming/2003 (H3N2) that occur in both naı ¨ve and
immune animals for the dual purposes of assessing the model for
recapitulation of virus evolution in humans and identifying
evolutionary trends which can be used for prediction of future
strains and subsequent design of novel vaccine candidates.
Results
Immunization and infection of Guinea pigs
Guinea pigs were infected with influenza A/Wyoming/03/2003
prior to or after immunization with homologous purified HA
ectodomain protein. Theories on the mechanism by which
antigenic drift occurs in vivo are based largely on studies of the
HA sequence of natural variants and of mutants that escape in vitro
selection by anti-HA antibodies possessing virus neutralizing
activities [17]. Numerous reports have indicated that the HA
protein can mediate immunity from infection or disease and
suggest that the HA protein could become a viable subunit vaccine
candidate.
Selected groups of Guinea pigs were immunized by subcutane-
ous injection of purified recombinant HA ectodomain protein as
described in Materials and Methods. Anti-HA antibody serum
titers were followed to assess the immune status of the animals and
to quantitate immunological pressure against the HA glycoprotein.
Antigen-binding titers were measured by ELISA against commer-
cially produced HA (Protein Sciences, Inc.) and antiviral activities
were assessed by both hemagglutinin inhibition (HI) and virus
neutralization (VN) assays. Figure 1 demonstrates during the
course of the immunization phase for experimentally immunized
Group 2 animals, ELISA titers rose to 1:100,000, HI to 1: 2564,
and VN titers to 1:160. Sera from Guinea pigs in the mock
immunized, naive group (Group 1) did not increase in titer from a
baseline value of 1:10 for all three assays. After 25 weeks, the
Guinea pigs were inoculated intranasally with 10
4 plaque forming
units (PFU) of virus stock Wy-B4 produced from a plaque-purified
and sequenced isolate of the reassorted virus, A/Wyoming/03 X
PR8 X161B. The serological titers showed a slight increase after
inoculation with virus (week 25 to 27).
HA sequence data from progeny virus
The HA glycoprotein mediates virus-cell interactions and is the
antigenically dominant surface protein. During virus maturation,
the HA0 protein encoding by the HA gene is cleaved into HA1
and HA2 subunits. HA1 contains five defined epitopes involved in
immunity and the mutations occurring in HA1 play key roles in
virus escape from host immune pressure. A fragment (nt. 1–1,100)
of the influenza RNA segment 4 encoding the HA1 subunit and all
of the recognized HA epitopes was sequenced for the evolutionary
study.
Nasal washes collected 3 days post-infection (p.i.) were titrated
on MDCK cell monolayers to determine virus concentration.
Viral RNA was purified directly from nasal washes, reverse
transcribed, and used to produce molecular clones of the HA gene
fragment for sequencing. 514 independently derived plasmid
clones from naı ¨ve animals and 210 independently derived plasmid
clones from immunized animals were sequenced and compared to
the original sequence of the Wy-B4 HA gene. Table 1 contains a
summary of the sequence data. Complete lists of the mutated
strains are presented in Tables S1 and S2. Mean virus titers in
nasal washes of HA-immunized animals were reduced approxi-
Figure 1. Immunological analysis of Guinea pig serum pools.
Animals in Group 1 were inoculated with a mock preparation of antigen
(open symbols) and then infected with homologous influenza A/
Wyoming/03/2003.AnimalsinGroup2wereimmunizedwithrecombinant
HA compounded in Incomplete and Complete Freund’s adjuvant (solid
symbols) prior to infection. Serum pools were assayed for antigen binding
antibodies by ELISA against commercially prepared HA glycoprotein
(diamond). Antiviral activities were measured by both hemagglutinin
inhibition (square) and virus neutralization (triangle) assays. Arrows
underneath graph indicate dates of inoculation. Immunized Guinea pigs
were challenged with influenza virus on Week 25.
doi:10.1371/journal.pone.0020130.g001
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3
vs 10
4 pfu/mL). 6% of the plasmid clones sequenced from naı ¨ve
and 24.3% of the clones from immunized animals contained at
least one mutation in the sequenced HA.
Analysis of HA variants showed that of the mutations found in
naı ¨ve animals, 40.9% (27/66) did not affect amino acid changes
(synonymous) while 59.1% (39/66) caused an amino acid
substitution or deletion (non-synonymous). Conversely, mutations
from immune guinea pigs included 59.9% (94/157) synonymous
and 40.1% (63/157) non-synonymous changes (see table 1).
Interestingly, the average number of mutations per variant found
in naı ¨ve animals was 2.1 compared to 3.1 RNA mutations per
variant strain in immunized animals. The amino acid mutation
rate was calculated using the total number of non-synonymous
mutations observed per amino acid residue. The HA-1 mutation
rates for non-synonymous mutations in naı ¨ve and immune animals
were calculated to be 2.3610
24 and 9.0610
24 residues mutated
per amino acid, respectively.
Analysis of mutations for changes in charge and
hydrophobicity
The type of amino acid mutations that occur may either
facilitate or hinder antigenic escape and replicative fitness.
Sequence analysis of evolved influenza H3N2 HA from human
samples indicates that changes in charge or hydrophobicity
properties of the substituted amino acids in epitopes may be a
major driver of antigenic escape [18]. Therefore, the physical
properties of the mutations observed in progeny virus were
analyzed to determine whether such correlations can be found in
the variants observed in the progeny virus from Guinea pig
infections and, if so, whether the correlations reflect immune
status. Examination of mutations across the entire HA-1 regions
showed that a slightly higher percentage of the variants from
immunized animals involved charge changes compared to virus
progeny from naı ¨ve animals (Table 2, 55.6% vs. 48.7%).
Interestingly, a higher percentage of variants from naı ¨ve animals
had changes in the hydrophobicity state as compared to variants
from immunized Guinea pigs (33.3% vs. 11.1%). A Pearson Chi-
squared statistical analysis of these data suggests that the
differences in the percentage of charge changes between the two
groups are not significant (p.0.05) but differences between
hydrophobic states are significant (p,0.01).
Frequency of mutations by position
With the aim of identifying ‘‘hot spots’’ of variation, the position
of the mutations in the variants were tabulated by groups of 5
amino acids and graphed (Figure 2). As expected, the mutations
were not evenly scattered across the HA gene in a random pattern.
In the naı ¨ve group, the distribution of variants in the virus progeny
contained 18 sites with one variant, 6 sites with two, one site with
four, and 327 (92.9%) sites without variants. The distribution of
variants in the progeny from immunized animals showed 13 sites
with one variant, 12 sites with two, two sites each with either three,
four, or six, and 323 (91.5%) sites without variants. The Graphs in
Figure 2 indicate that in the progeny virus from immunized
animals there were four ‘‘hot spots’’ with a frequency of at least 4
or more mutations. The observation that multiple strains
contained variants in these positions suggest that immune
pressures are the highest at these sites. The region from 75–80
region had mutations Q75R, C76R, D77G and D77N; 125–130
had two at N126D and four at G129E; 165–170 had one N165G,
one N165S, two T167A, two P169L; and region 225–230 had one
I226V, one R228D and two R229D (See also Tables S1 and S2
for complete list of variants). The regions of the highest frequency
of variations (hot spots) have been localized on crystallographic
structures of the HA ectodomain using the related structure from
H3N2 strain X31 (Figure 3, adapted from 2VIR.pdb, [19]). In
Figure 3, epitopes are colorized and the hot spots of variation
shown as balls for progeny virus from naı ¨ve (Panel A) and
immunized Guinea pigs (Panel B). The figure shows that the
majority of the hot spots are on the surface of the HA molecule
and in epitope regions.
Association of mutations with epitopes
A growing body of published data from the analysis of human
viruses indicates that the process of influenza is not random and
that the majority of selected variability occurs in the epitopes. The
location of the five major epitopes of the HA glycoprotein has been
determined [6,20]. The effect of immunological pressure on the
relative ratios of mutations accumulated in infected Guinea pigs
within and outside the five defined epitopes was examined
(Figure 3). Variants isolated from immunized animals had a
higher percentage of mutations within the defined epitopes as
compared to naı ¨ve Guinea pigs (38.5% vs. 63.5%). In addition, the
types of amino acid changes found in the variants were also
different in progeny virus sampled from immunized and naı ¨ve
animals. Overall, the fraction of mutations that altered the charge
of the residue was 65.7% and 42% in immunized and naive
Guinea pigs respectively. Furthermore, hydrophobicity was
affected by 71.4% and 38.5% of the mutations, in immunized
and naı ¨ve animals.
Analysis of mutants for changes in putative glycosylation
Changes in glycosylation are associated with biological
properties such as the folding and assembly of trimeric HA
macromolecules, recognition of cell receptors, and evasion of host
immunity. The number of putative glycosylation residues in
circulating H3N2 influenza virus isolates has increased with time
from seven glycosylations in the 1968 Aichi strain to eleven in the
Table 1. Sequence analysis of progeny virus from influenza infection of guinea pigs.
Animal group
Immune
status
Nasal titers
(pfu/ml)
Sequenced
HA-1 genes HA variant strains Total
Synonymous
mutations
Non-synon.
mutations
Group 1 Naı ¨ve 104 514 31(6.0%) 66 27(40.9%) 39(59.1%)
Group 2 immunized 103 210 51(24.3%) 157 94(59.9%) 63(40.1%)
Statistical P,0.01 Statistical P,0.01 P,0.01
significance p=2.017610
212 significance p=9.5610
23 p=9.5 610
23
(X2) (Significant) (X2) (Significant) (Significant)
doi:10.1371/journal.pone.0020130.t001
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Table 3 shows the number of changes to variants that affected the
putative_glycosylation status of the HA protein with the
identification of the site of the mutation. Of the variants isolated
from naı ¨ve Guinea pigs, one each lost and gained a putative_
glycosylation site. In contrast, five variants from immunized
animals lost, and none gained, a putative glycosylation site. It is
interesting to note that putative glycosylation sites at 248, 128,
and 135 glycosylation sites are used in the Wyoming strain, but
not its predecessors Aichi or X31 from 1968. In Figure 4, the sites
of putative glycosylation change found in the progeny variants
from immunized animals are identified in color and with arrows.
As expected, the majority of the changes that could affect
glycosylation status are seen on the surface of the HA molecule
and in epitopes.
Discussion
Influenza viruses must escape from the immune pressure by
antigenic variation to propagate over time in the population of
host targets. The high mutation rate of RNA viruses appears to
provide a ready supply of variants, some of which may have
replicative advantages in the face of host immunity [21,22].
Analysis of naturally occurring variants isolated from infected
humans and other species has led to the identification of ‘‘hot
spots’’ of mutation that are hypothesized to define amino acid
residues associated with antigenic epitopes [21,23,24,25]. The
most variable of the residues are predicted to reside within the
dominant epitopes and these epitopes, for the most part, have been
confirmed by immunological studies and the data within these
experiments. Multiple strategies have been employed to charac-
terize immunodominant epitopes in viruses [11]. But due to the
complexity of characterizing the evolution of influenza virus
through infection of human hosts, there is great value in studying
experimental infections in animal models [24]. In the current
study, we surveyed progeny virus directly from Guinea pigs
infected with influenza virus by sequencing multiple HA genes
without passage through cell culture passage. Rather than
characterizing the most common sequence at each residue by
bulk sequencing of mixed templates, we sampled individual
progeny to uncover specific variants. Because the majority of
natural variations observed during passage of influenza virus
through the human population reside in the globular head of the
HA, the study was limited to analysis of the HA-1 subunit The
methodology used to characterize the variants (sequencing small
libraries of cDNA amplicons) does distinguish between different
fitness levels of progeny variants. Although it is possible that some
of the mutations may have reduced replicative fitness, the ‘‘hot
spots’’ observed are in regions of high genetic and structural
flexibility known to tolerate variations and mutations.
As expected, infection of HA-immunized Guinea pigs resulted
in the selection of a higher percentage of progeny strains
containing variations in the HA protein sequences as compared
to unimmunized animals (24.3% vs. 6.0%, Table 1). Of the 396
residues of the HA-1 subunit analyzed during these studies, 265
amino acids, or 67%, are outside and 131 residues, or 33%, are
inside epitopes. 61.5% of the mutations characterized from the
nasal washes of naı ¨ve animals were located in amino acid residues
Table 2. Analysis of amino acids in HA variants.
Animal Group Immune Status Total Variants Charge Changes Hydrophobicity Changes
1N a ı ¨ve 39 19 (48.7%) 13 (33.3%)
2 Immunized 63 35 (55.6%) 7 (11.1%)
Statistical P.0.05 P,0.01
significance p=0.537 p=0.006013
(X2) (Not Significant) (Significant)
doi:10.1371/journal.pone.0020130.t002
Figure 2. Histogram of influenza mutations by HA amino acid residue. Bars show the number of mutations at each amino acid observed in
variants isolated from nasal washes of influenza virus infected Guinea pigs by sets of five residues as numbered. Panel A: variants from naı ¨ve Guinea
pigs, Panel B: variants from HA-immunized animals. Blue stars above bars indicate mutations that occurred within known epitopes. Red stars above
bars indicate mutations that occurred outside known epitopes.
doi:10.1371/journal.pone.0020130.g002
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immune pressure, the location of the variations resembled a
random distribution. In contrast, 63.5% of the mutations found in
immunized animals were within epitopes; their frequency was
approximately twice the rate expected (33%) for a random
distribution (data not shown).
In addition to an analysis of the frequency and antigenic
location of mutations, the physical properties of the amino acid
substitutions were analyzed. Amino acids that change local
electrostatic charge or hydrophobicity can have major effects on
the recognition of epitopes by existing antibodies. Mutations that
change these two properties can facilitate evolutionary escape and
the formation of new strains of virus. In naı ¨ve animals,
approximately 42% of amino acid substitutions that resulted in a
change in electrostatic charge were in epitopes while 65.7% of the
charge changes in progeny virus from immunized Guinea pigs
were in epitopes. Similarly, 37.5% of the mutations changing the
hydrophobic nature of the residue were in epitopes in naı ¨ve
animals, and 71.4% were in the epitopes of immunized Guinea
pigs (Figure 5). The pattern of influenza evolution in Guinea pigs
correlated with mutations observed in H3N2 strains sequenced
from human samples. Much of the evolution of influenza in both
species involved substitutions of charged or hydrophobic amino
acid residues or mutations that led to changes in glycosylation
profile [18]. Influenza virus undergoing escape evolution in
Guinea pigs also showed a tendency to substitute the amino acids
in the epitope regions, which was also observed in human
influenza [6,27]. Consequently, the evolution of the virus in
Guinea pigs represents a valuable model system for helping us to
understand the escape evolution of human influenza virus. These
results conformed nicely to recent analyses of sequences from
human clinical isolates of H3N2 during its evolution from 1968
[18].
The HA has accumulated glycosylations during the evolution of
H3N2. Over the past 40 years, the number of glycosylation signals
has increased from 7 (Aichi/68) to 13 (Brisbane/2007) and
appears to be one method by which a virus can mask its epitopes
from immune surveillance [28,29]. In addition, some studies have
associated increasing glycosylations with reduced virulence [29,30]
while others associated the loss of glycosylations with exposure of
new receptor binding sites or new decoy epitopes [31]. Michele et
al (1993) reported the role of glycosylation in the control of host
range and suggest that oligosaccharides on the tip of the HA are
important to the survival of H1 viruses in humans but not in ducks
or swine [32]. In the Guinea pig study, one of the strains from the
naı ¨ve group gained a glycosylation and one lost a glycosylation
(Table 3). In contrast, five of the strains from the immunized group
lost glycosylation sites. Glycosylations were lost at one site each in
the A, B, and D epitopes (T135, N165, and T167, respectively).
Although the reasons for, and consequences of, changes to
glycosylation density during evolution in humans remains unclear,
it appears that the reduction in glycosylations in the major
epitopes have facilitated escape from immune pressure or
increased the rate of replication.
The analysis of mutation frequency identified four hot-spots of
mutation regions in this study (Figure 4). It is possible that these
sites of high variation enable the virus to stimulate strain-specific
immunity. As such, they could be regarded as immunological
‘‘decoys’’ to prevent the host from developing durable immunity
against multiple strains of H3N2 virus. During viral infection, the
immune system appears to react preferentially against immuno-
dominant epitopes which, in the case of influenza HA, are
composed of genetically variable amino acids. It appears that
influenza, and many other pathogens, have evolved to take
advantage of weaknesses in the immune system caused by
antigenic hierarchy. Recent studies have shown that rarely
occurring antibodies can be isolated or produced that recognize
highly conserved epitopes in the stalk regions of HA (HA2) [42].
We hypothesize that influenza, and other viruses that exist as
antigenic swarms, have evolved such that the many of the sites that
are indispensable for replication and require a high degree of
genetic conservation are also poorly immunogenic. Thus, the
stimulation of immunity to variable regions allows the virus to
antigenically escape and, thus, the host is susceptible to antigenic
variants in succeeding exposures. The observations presented
herein are consistent with the results of David et al, who proposed
that the evolvability of virus is a selectable trait [33].
For reasons still unexplained, the host immune system responds
to many pathogens, such as influenza, by mounting a relatively
oligoclonal response that is focused upon a small number of
immunodominant epitopes [34]. We propose that influenza
viruses evolved to take advantage of host immunological hierarchy
by placing immunodominant epitopes within regions, such as
unconstrained loop structures, that can accept a high degree of
diversity without major decreases in replicative fitness. Thus,
through relatively modest mutations in a very small number of
amino acid residues, influenza can antigenically escape immune
pressure. If the host could mount a truly polyclonal immune
response that recognizes a large number of sites in the HA,
including those that are normally sub-dominant, perhaps influenza
would not elicit strain-specific immunity.
Several strategies are in development to counteract strain-
specific immunity for the development of broadly cross-reactive
vaccines. Vaccines targeting more conserved proteins, such as the
M2, or those containing improved adjuvants have produced a
Figure 3. Location of most frequently occurring variants on 3D
structure. Amino acids in the epitopes of the ribbon diagram of the
HA protein from the related H3N2 strain X31 was colorized such that
Epitope A=Yellow, B=Red, C=Blue, D=Green, and E=Pink. Amino
acid residues with the highest frequency of variation are shown as balls.
Panel A shows mutations from naı ¨ve Guinea pigs and Panel B from
immunized animals. Figure drawn using PyMOL from 2VIR.pdb [19].
doi:10.1371/journal.pone.0020130.g003
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[26,35,36]. In addition, a rational antigen design strategy
designated, the Immune Refocusing Technology, represents a
highly promising approach to the development of broadly
protective vaccines [7,37,38]. In applications with influenza,
Tobin et al have antigenically dampened multiple immunodomi-
nant HA epitopes of the A/Wyoming/2003 strain to engineer an
initial panel of vaccine candidates that stimulate enhanced cross-
reactive antiviral responses to other H3N2 strains [7]. The hot
spots of mutation, and the sites that lost glycosylations, identified in
the present study are potential targets of Immune Refocusing for
the development of improved vaccines.
Conclusion
HA specific immunity plays a key role in H3N2 virus evolution.
The fixation of mutations of H3N2 virus in both naı ¨ve and immune
animal appeared to be non-random events as immune pressure can
lead to mutations accumulating in dominant epitopes. We found
that the mutations driven by immunity are frequently associated
with charge, hydrophobicity, and lost glycosylations. The results of
the present study increase our understanding of the direction of
evolution in influenza and may provide useful insights for the
selection of strains to be included in the seasonal vaccine.
Materials and Methods
Ethics statement
All proposed animal work was reviewed by the Biological
Mimetics, Inc. Institutional Animal Care and Use Committee.
I-ACUC approval was obtained prior to initiation of animal work.
All animal work was conducted in accordance to national and
international guidelines to minimize discomfort to animals.
Cells and viruses
MDCK cells (ATCC # CCL-34) were used for virus
propagation and titration, and were maintained in DMEM
Table 3. Analysis of amino acid substitutions in HA variants.
Animal groups Immune status Loss of glycosylation Gain of glycosylation
Group 1 Naı ¨ve 1 (T248P) 1 (A128T)
Group 2 immunized 5 (N165S, N165G, T167A, T167A, T135A) None
doi:10.1371/journal.pone.0020130.t003
Figure 4. Analysis of Glycosylations. Space-filled model of HA ectodomain from related H3N2 strain X31 drawn with PyMOL using 2VIR.pdb [19].
Panel A shows the H3N2 glycosylation sites of the wild type Wyoming/2003, Panel B shows glycosylation site changes in the naı ¨ve Guinea pigs, and
Panel C shows glycosylation site changes in the immunized Guinea pigs. Epitopes A, B, C, D, E are shown colorized in yellow, red, blue, green and
pink, respectively. Receptor binding site is shown as mesh. Residues at which glycosylation sites were either lost during the evolution of the virus in
Guinea pigs are shown in cyan, or sites that were added in purple.
doi:10.1371/journal.pone.0020130.g004
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Wyoming/03 X PR8 X161B virus was obtained from the Centers
for Disease Control and Prevention (CDC). The stock is a
biological re-assortment of A/Wyoming/03/2003 (WYM) and A/
Puerto Rico/8/1934 (PR8) and was prepared for the development
of vaccine preparations by double infection of embryonated hens’
eggs following antibody selection methods [39]. Sequence analysis
of multiple plaques from the CDC stock demonstrated that the
material was heterogenous in HA gene sequence. In order to
prepare a homogeneous virus for infection of Guinea pigs, several
parallel plaque-purified isolates were propagated, sequenced, and
titered. The isolate used in the current study, Wy-B4, is a plaque-
purified isolate from Wyoming/03 X PR8 X161B and carries an
HA gene segment identical to the GenBank sequence (accession
number AAT08000).
Plaque assays
Plaque assays were used for purification of virus isolates and
quantitation of virus propagated both in vitro and in the Guinea
pig. Briefly, 6-well plates were seeded at 50% confluence with
MDCK cells. The following day, serial dilutions of influenza virus
were applied in 1-mL volumes for 1 hour. The monolayers were
washed with PBS and overlain with a solution of 0.8% agarose in
EMEM supplemented with 3.5% FBS and 0.1% neutral red.
Clear plaques were visible against the stained cells after 3–4 days
incubation at 37uC. The Wy-B4 isolate was purified from a well-
separated plaque and propagated on fresh cultures of MDCK.
Virus stocks were titered in MDCK cells prior to use in animals.
Guinea pig Immunizations
Guinea pigs were immunized with recombinant HA ectodo-
main protein derived from the Wyoming/03/2003 virus. Briefly,
the HA gene from the Wyoming virus was truncated at the
transmembrane domain and cloned into the insect cell expression
vector, pMT-BiP (Invitrogen). Induction of stably transfected S2
drosophila cells led to the soluble expression of ectodomain
proteins that appear to assemble into trimeric structures by small
angle X-ray scatter (SAXS analysis, data not shown). The
recombinant protein was purified by sequential His-tag selection
on metal activated sepharose, lentil lectin agarose, and DE-53
anion exchange resins. A mock preparation of antigen was
prepared by the same manner using empty pMT-BIP vector.
Harlan Sprague Guinea pigs, 6–8 weeks of age, were obtained
(Harlan-Spraque-Dowley, Inc.) and divided into two groups.
Group 1 was given the mock antigen and served as a negative
control for the experiment. Group 2 was given the HA
recombinant ecto domain protein. The purified protein was
compounded with Complete Freund’s Adjuvant for initial
immunizations and Incomplete Freund’s Adjuvant for boosts at
weeks 3, 5, and 10. Serum samples were taken periodically
throughout the study for serological analysis.
Guinea pig infection and nasal wash collection
All of the animal work was performed at BioCon, Inc.
(Rockville, MD) under AAALAC guidelines and I-ACUC- and
ACURO-approved animal study protocol documents. Approval of
BMI I-ACUC study protocols preceded the initiation of any
animal work. Lightly anesthetized Guinea pigs, naı ¨ve or
immunized, were inoculated intranasally with approximately 10
4
plaque forming units (PFU) of the Wy-B4 isolate in 0.3 mL
volumes of sterile saline. Virus progeny were sampled by nasal
irrigation of anesthetized Guinea pigs using 0.5 mL PBS
supplemented with 100 ug/mL penicillin, 100 ug/mL streptomy-
cin and 0.3% bovine serum albumin [8]. Nasal washes were
clarified of debris by centrifugation at 1,6006g for 10 min and
stored at 280uC prior to analysis. Where noted, Guinea pigs were
re-infected after a 6-week recovery period using the same dose and
route.
ELISA Analysis of Guinea Pig Sera
Immune responses were monitored by ELISA method. Briefly,
Nunc Maxisorb flat-bottom 96-well plates were coated overnight
with full-length A/Wyoming/03/2003 HA protein (Protein
Science Corporation) at a concentration of 1.5 micrograms in
0.1 mL of PBS per well. The plates were washed in PBS
containing 0.1% Tween-20 (PBS-T) and then nonspecific binding
blocked with 0.2 mL/well of 10% nonfat dried milk in PBS for 2 h
at 37uC. Serum samples were serially diluted in 1% milk solution
Figure 5. Relationships between frequency of HA mutations, epitopes, and charged or hydrophobic amino acids. Bars show frequency
of mutations at each amino acid observed in variants isolated from nasal washes of influenza virus infected Guinea pigs. Frequency calculated by
dividing number of mutations at a given residue with the total number of variants observed. Panel A: variants from naı ¨ve Guinea pigs, Panel B:
variants from HA-immunized animals.
doi:10.1371/journal.pone.0020130.g005
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wells. Plates were incubated for 1 h at 37uC and then washed
again using PBS-T. The plates were probed with a peroxidase-
conjugated goat anti-Guinea pig total IgG antibody (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD, KPL, 1:1000) for 1 h
and then washed again with PBS-T. Bound conjugates were
quantitated by the addition of 0.1 mL tetramethylbenzidine
(TMB) substrate (KPL) for 90 sec, immediately followed by an
equal volume of 0.1 N sulfuric acid. Plates were read at 450 nm.
The triplicate well values were used to calculate mean average
values. Values from antigen-coated wells reacted with secondary
antibody, but not test sera, were used as plate background values
and were subtracted from absorbance values in test wells. ELISA
extinction titers were calculated as the maximum serum dilutions
that resulted in a signal that exceeded a value that was three times
plate background (approximately 0.15 OD units). Mean values
with error bars equal to one standard deviation of the triplicate
were graphed as a function of time over the course of the study
and, due to their small magnitudes, may not be visible on the
graphs.
Virus Microneutralization (VN)
Detection of serum neutralizing antibodies was determined by a
standard method [40], with a few modifications. Briefly, in a 96-
well plate, two-fold dilutions (10 ml volume) of RDE-treated sera
were prepared over a concentration range of 1:20–1:2560 in assay
diluent (1% bovine serum albumen in PBS containing penicillin
and streptomycin). The plate was incubated with A/Wyoming
virus (100 TCID50) for 2 hrs at 37uC. MDCK cells (3610
4) were
added and incubated 18 hrs at 37uC, 5% CO2. The cells were
fixed with 80% acetone, blocked with assay diluent containing 1%
Tween-20, and probed for nucleoprotein (NP) with mouse anti-
influenza antibodies (1:4000 final concentration of 1:1 MAB8258
and MAB8257, Millipore, Billerica, MA). After extensive washing,
goat anti-mouse IgG HRP (1:2000, Jackson Labs, West Grove,
PA) was added for 1 hr at RT followed by color development by
quantification using tetramethylbenzidine (R&D System, Minne-
apolis, MN). Absorbance was read at 450 nm.
Hemagglutination Inhibition Assay (HI)
A standard HI assay was performed in blinded fashion to assess
antiviral antibodies [41]. Prior to assay, serum samples were
treated with Receptor Destroying Enzyme (RDE, Denka Seiken
CO LTD., Tokyo, Japan) overnight at 37uC followed by heat
inactivation for 1 hour at 56uC. Two-fold dilutions of serum
samples were mixed with A/Wyoming/03/2003 virus (at a
concentration of 4 hemagglutination units per well) and incubated
for 15 min at room temperature. 0.05 mL of a 0.5% suspension of
chicken red blood cells was added and hemagglutination was
assessed after 1 h, as described.
Sequences analysis
Viral RNAs were extracted from nasal wash and tissue culture
samples using the RNA Easy Kit (Qiagen). cDNAs were
synthesized using Superscript reverse transcriptase (Invitrogen)
and the following positive strand primer: 59-ATGAAGACTAT-
CATTGCTTTAAG-39. HA cDNA fragments were amplified by
PCR using the above oligonucleotide with the negative strand
primer: 59-CGCGATTGCGCCAAATATGCC-39 and a maxi-
mum number of 18 cycles. Pfu polymerase (Stratagene) with
proofreading activity was used to minimize mutations introduced
in the PCR amplificaiton process. The 1056-nt fragment of gene
segment 4 containing the HA-1 coding region for was cloned into
the TOPO TA vector (Invitrogen) and independent colonies were
selected for DNA sequencing. DNA sequences of the HA1
fragments were compared to the original sequence of the
Wyoming/03/2003 HA1 gene fragment (Genbank accession
number AAT08000).
Data analysis
A Chi-squared statistical analysis of homogeneity was used to
test the hypothesis that two percentages of mutations are equal
between different test groups. The formula used for the test is:
X2~
X n
i~1
Oi{Ei ðÞ
2
Ei
where n=number of samples in set, A=the probability (p)
assigned to the null hypothesis that there is no difference between
the two sets of data. As a test of statistical significance, a confidence
level of 95%, p,0.05, was applied.
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